grincamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

grincamycin: structure given in first source; isolated from Streptomyces griseoincarnatus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	70691549
CHEMBL ID	2011815
MeSH ID	M0154707

Synonyms (2)

Synonym
grincamycin
CHEMBL2011815

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID654900	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32.
AID654898	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32.
AID654897	Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32.
AID654899	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32.
AID654896	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32.
AID654895	Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay	2012	Journal of natural products, Feb-24, Volume: 75, Issue:2	Cytotoxic angucycline class glycosides from the deep sea actinomycete Streptomyces lusitanus SCSIO LR32.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (10.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (50.00)	24.3611
2020's	4 (40.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.07	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
os-4742a(1) vineomycin A1: from Streptomyces strain No. 1894; structure in second source	2.08	1
saquayamycin saquayamycin: isolated from Streptomyces nodosus MH190-16F3; structure given in first source	2.21	1
tetrangomycin tetrangomycin: RN given for (+)-isomer; structure in first source. tetrangomycin : An angucycline antibiotic that is 3,4-dihydrotetraphene-1,7,12(2H)-trione substituted by hydroxy groups at positions 3 and 8 and a methyl group at position 3 (the 3R stereoisomer) ring system. It is an antibiotic isolated from Streptomyces sp.	2.08	1
galtamycin galtamycin: isolated from Streptomyces species; shows low antitumor activity; inactive against fungi and gram-positive and gram-negative bacteria	2.21	1
rabelomycin rabelomycin: structure	2.17	1
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.17	1	actinomycin	mutagen
glycosides [no description available]	2.21	1
rhodinose rhodinose: structure in first source	7.08	1	trideoxyhexose
saquayamycin b saquayamycin B: isolated from Streptomyces nodosus MH190-16F3; structure given in first source	2.21	1

Condition	Relationship Strength	Studies
Benign Neoplasms, Brain [description not available]	2.25	1
Astrocytoma, Grade IV [description not available]	2.25	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.25	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.25	1
Ascites, Gelatinous [description not available]	2.31	1
Pseudomyxoma Peritonei A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).	2.31	1
Breast Cancer [description not available]	2.21	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.21	1

chemdatabank.com